The high stakes of pricing a coronavirus drug

Now that the federal government is allowing the emergency use of remdesivir for coronavirus patients, and as the world awaits final clinical data on the drug’s effectiveness, a giant question looms: What will the price be?

Why it matters: Gilead’s pricing decision is important on its own, but it also will set the bar for how all coronavirus treatments that come after remdesivir will be priced, Axios’ Bob Herman reports.

Continue reading on Axios.